

What is Claimed is:


1. A method of treating a chronic disease in a mammal in need thereof, which disease is characterized by excessive, undesired or inappropriate angiogenesis, with an effective amount of a compound which inhibits the production, transcription, translation, or activity of 14 kDa PLA₂.

2. The method according to Claim 1 wherein the disease is diabetic retinopathy and other ocular neovascularizations.

3. The method according to Claim 1 wherein the disease is tumor growth and metastasis.

4. The method according to Claim 1 wherein the disease is atherosclerosis.

5. The method according to Claim 1 wherein the compound is of the formula:



wherein

R₁ is (CH₂)_nOH or (CH₂)_nCO₂R₈,

n is 0 or an integer a value of 1;

X is oxygen or sulfur;

R₂ is hydrogen, halogen, optionally substituted C₁₋₈ alkyl, or C₁₋₈ alkoxy;

m is 0 or an integer having a value of 1 or 2;

R₃ is S(O)₂ R₇;

R₄ is hydrogen or S(O)₂ R₇;

R₅ is hydrogen, halogen, CF₃, CH₃, (CH₂)_tC(O)₂R₉, or (CH₂)_tOH;

t is 0 or an integer having a value of 1 or 2;

R₆ is hydrogen or halogen;

R₇ is optionally substituted aryl, optionally substituted arylC₁₋₂ alkyl, or an optionally substituted C₁₋₈ alkyl;

R₈ is hydrogen or C₁₋₄ alkyl;

R₉ is hydrogen or C₁₋₄ alkyl;
or a pharmaceutically acceptable salt thereof.

6. The method according to Claim 5 wherein the compound is 2-[2-[3,5-
5 bis(Trifluoromethyl)phenylsulfonamido]-4-trifluoromethylphenoxy]benzoic acid, or
a pharmaceutically acceptable salt thereof.

A handwritten signature in black ink, consisting of stylized, overlapping loops and a long horizontal stroke extending to the right.